Medical data company Tempus has launched the first cardiology prospective study for its investigational AI-enabled predictive cardiology tests.
Titled ‘Electrocardiogram-based Artificial Intelligence-Assisted Detection of Heart Disease’ or ECG-AID, the study aims to investigate whether using a machine learning model in a clinically acquired electrocardiogram (ECG) can improve its functionality.
It will focus on identifying patients who are at high risk of developing atrial fibrillation (AFib) or one of seven structural heart diseases (SHD), including aortic and tricuspid valves, abnormal heart thickening, abnormal heart function and mitral diseases.
Tempus’ predictive, AI-enabled technology aims to help clinicians find patients suffering from undiagnosed heart disease, which can lead to strokes and other debilitating outcomes.
In the ECG-AID study, Tempus is evaluating its AI-enabled algorithmic tests in collaboration with a network of healthcare providers and cardiologists, including Geisinger and TriHealth.
Through this, the company aims to determine the impact of identifying patients who are at high risk of developing cardiovascular disease.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
People who have received a 12-lead ECG during their routine clinical care are eligible to enrol in the ECG-AID study.
Tempus’ investigational ECG Analysis Platform algorithms will examine the participants’ ECG data for identifying the people who are at high risk of developing heart disease.
Participants aged older than 65 years with no known history of AFib who are identified as high risk will receive iRhythm’s long-term, continuous cardiac monitor, ZioXT.
This will be used to evaluate for AFib and other abnormal heart beats.
In addition, people aged older than 40 years with no prior history of SHD who are identified as high risk will undergo an echocardiogram.
Tempus Clinical Cardiology vice-president John Pfeifer said: “As a practicing cardiologist, I’m excited to be launching a study with the goal of finding treatable heart disease before it is too late.
“We owe it to patients to build technology like the Tempus ECG Analysis Platform to deliver on the promise of data-driven precision medicine.”